<DOC>
	<DOC>NCT02364310</DOC>
	<brief_summary>Medico-economics assessment (cost-effectiveness) of the unilateral carotid barostimulation with Barostim NeoTM compared to usual care in patients with resistant hypertension (multicenter randomized, PROBE trial), followed-up for 12 months, with a lifetime-long modeling.</brief_summary>
	<brief_title>Economic Evaluation of Baroreceptor STIMulation for the Treatment of Resistant HyperTensioN</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Main inclusion Criteria: 1875 y old men or women Resistant hypertension on 4 medications incl. thiazide or thiazidelike diuretics at appropriate doses + spironolactone (unless spironolactone intolerance) Essential hypertension documented (bilan &lt; 2 years old) eGFR ≥ 30 ml/min/1,73 m2 No carotid condition associated with a contraindication for Barostim NeoTM use Main exclusion Criteria: Patients with documented secondary hypertension, besides Obstructive Sleep Apnea Symptomatic orthostatic hypotension Patient with prior syncope or myocardial infarction, unstable angina pectoris, or cerebrovascular within 3 months before inclusion Patient with type 1 diabetes mellitus Patient with permanent atrial fibrillation Patient with brachial circumference of ≥ 46cm Patient with BMI&gt;45kg/m2 Pregnancy, breastfeeding or planning a pregnancy within 2 years NeoTM implantation anatomic contraindications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>baroreceptor stimulation</keyword>
	<keyword>Hypertension resistant</keyword>
</DOC>